Bio-Techne Corp $TECH Shares Acquired by Teacher Retirement System of Texas

Market Beat
2025.11.04 08:29
portai
I'm PortAI, I can summarize articles.

Teacher Retirement System of Texas increased its stake in Bio-Techne Corp (NASDAQ:TECH) by 52.5% in Q2, owning 35,414 shares valued at $1.82 million. Other investors also raised their positions. Bio-Techne's stock is down 2.1%, with a market cap of $9.54 billion and a PE ratio of 133.18. The company reported Q2 earnings of $0.53 EPS, beating estimates, and announced a quarterly dividend of $0.08. Analysts have mixed ratings, with an average target price of $70.58.

Teacher Retirement System of Texas grew its stake in Bio-Techne Corp (NASDAQ:TECH - Free Report) by 52.5% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 35,414 shares of the biotechnology company's stock after buying an additional 12,187 shares during the quarter. Teacher Retirement System of Texas' holdings in Bio-Techne were worth $1,822,000 as of its most recent SEC filing.

  • Bio-Techne, J2 Global And InMode Break Out Of Bases, Near Buy Points

A number of other large investors also recently bought and sold shares of TECH. Nisa Investment Advisors LLC grew its position in shares of Bio-Techne by 8.4% in the second quarter. Nisa Investment Advisors LLC now owns 67,958 shares of the biotechnology company's stock valued at $3,496,000 after purchasing an additional 5,250 shares in the last quarter. State of New Jersey Common Pension Fund D boosted its position in shares of Bio-Techne by 1.6% during the second quarter. State of New Jersey Common Pension Fund D now owns 52,511 shares of the biotechnology company's stock worth $2,702,000 after buying an additional 844 shares during the period. Sage Mountain Advisors LLC purchased a new position in Bio-Techne in the second quarter valued at $230,000. AlphaQuest LLC boosted its holdings in Bio-Techne by 392.5% in the second quarter. AlphaQuest LLC now owns 2,822 shares of the biotechnology company's stock valued at $145,000 after purchasing an additional 2,249 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. raised its stake in Bio-Techne by 15.7% in the second quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,349,712 shares of the biotechnology company's stock valued at $120,893,000 after buying an additional 319,177 shares in the last quarter. Institutional investors and hedge funds own 98.95% of the company's stock.

Bio-Techne Stock Down 2.1%

Shares of NASDAQ TECH opened at $61.26 on Tuesday. Bio-Techne Corp has a 52-week low of $46.01 and a 52-week high of $80.80. The firm has a fifty day moving average of $57.34 and a 200-day moving average of $53.53. The stock has a market capitalization of $9.54 billion, a PE ratio of 133.18, a P/E/G ratio of 3.63 and a beta of 1.48. The company has a quick ratio of 2.38, a current ratio of 3.46 and a debt-to-equity ratio of 0.18.

Bio-Techne (NASDAQ:TECH - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported $0.53 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.50 by $0.03. Bio-Techne had a net margin of 6.02% and a return on equity of 13.43%. The company had revenue of $316.96 million during the quarter, compared to analysts' expectations of $315.14 million. During the same period in the previous year, the company earned $0.49 EPS. The business's quarterly revenue was up 3.6% compared to the same quarter last year. On average, analysts anticipate that Bio-Techne Corp will post 1.67 EPS for the current year.

Bio-Techne Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, August 29th. Shareholders of record on Monday, August 18th were issued a $0.08 dividend. The ex-dividend date was Monday, August 18th. This represents a $0.32 dividend on an annualized basis and a yield of 0.5%. Bio-Techne's payout ratio is currently 69.57%.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on TECH. Weiss Ratings reiterated a "sell (d+)" rating on shares of Bio-Techne in a report on Wednesday, October 8th. Scotiabank lowered their price objective on Bio-Techne from $90.00 to $75.00 and set a "sector outperform" rating on the stock in a report on Friday, July 11th. Zacks Research raised Bio-Techne from a "strong sell" rating to a "hold" rating in a report on Monday, October 6th. Stephens raised Bio-Techne to a "strong-buy" rating and set a $65.00 price target on the stock in a research note on Tuesday, July 22nd. Finally, Cowen restated a "buy" rating on shares of Bio-Techne in a research report on Tuesday, October 14th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $70.58.

Read Our Latest Stock Report on TECH

About Bio-Techne

(Free Report)

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.

Featured Articles

  • Five stocks we like better than Bio-Techne
  • Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
  • Semiconductor Supercycle: Why Onsemi Stock Could Double as AI and EV Growth Accelerate
  • Mastering Discipline: Overcoming Emotional Challenges In Trading
  • The Best Local Butchers for Thanksgiving [2025 Survey]
  • Why Are Stock Sectors Important to Successful Investing?
  • $134M in Insider Moves: What It Might Mean for KMI, ISRG and QS

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Bio-Techne Right Now?

Before you consider Bio-Techne, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bio-Techne wasn't on the list.

While Bio-Techne currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Source: Market Beat The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.